LivaNova (NASDAQ:LIVN) Upgraded at Freedom Capital

Freedom Capital upgraded shares of LivaNova (NASDAQ:LIVN) to a hold rating in a report published on Tuesday morning,Zacks.com reports.

LIVN has been the subject of several other reports. Robert W. Baird decreased their price target on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. KeyCorp lifted their price target on shares of LivaNova from $83.00 to $92.00 and gave the stock an “overweight” rating in a report on Monday, June 22nd. Barclays increased their price objective on LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a report on Thursday, May 7th. Mizuho raised their target price on LivaNova from $85.00 to $90.00 and gave the stock an “outperform” rating in a research report on Thursday, May 7th. Finally, Weiss Ratings upgraded LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research report on Thursday, May 7th. Six analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, LivaNova has an average rating of “Moderate Buy” and an average price target of $80.75.

LivaNova Stock Performance

NASDAQ:LIVN opened at $83.62 on Tuesday. The stock’s 50-day moving average is $73.58 and its 200-day moving average is $67.51. LivaNova has a 1-year low of $41.01 and a 1-year high of $83.98. The company has a current ratio of 1.33, a quick ratio of 1.11 and a debt-to-equity ratio of 0.24. The stock has a market cap of $4.59 billion, a P/E ratio of 42.88 and a beta of 0.86.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $0.13. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The business had revenue of $362.26 million during the quarter, compared to analyst estimates of $346.05 million. During the same quarter last year, the business earned $0.88 EPS. The firm’s quarterly revenue was up 14.3% on a year-over-year basis. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. Equities research analysts anticipate that LivaNova will post 3.73 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Francesco Bianchi sold 1,800 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total transaction of $136,350.00. Following the completion of the sale, the director owned 7,228 shares of the company’s stock, valued at $547,521. This trade represents a 19.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.35% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On LivaNova

Several institutional investors have recently added to or reduced their stakes in the business. Pacer Advisors Inc. grew its position in shares of LivaNova by 4.1% during the 1st quarter. Pacer Advisors Inc. now owns 17,336 shares of the company’s stock worth $1,102,000 after buying an additional 675 shares during the period. Segall Bryant & Hamill LLC bought a new stake in shares of LivaNova in the 1st quarter valued at $665,000. Janus Henderson Group PLC lifted its position in shares of LivaNova by 1,978.8% during the 1st quarter. Janus Henderson Group PLC now owns 471,379 shares of the company’s stock valued at $29,961,000 after acquiring an additional 448,703 shares during the period. EverSource Wealth Advisors LLC lifted its position in shares of LivaNova by 103.6% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,623 shares of the company’s stock valued at $103,000 after acquiring an additional 826 shares during the period. Finally, California State Teachers Retirement System boosted its stake in LivaNova by 24.3% during the first quarter. California State Teachers Retirement System now owns 63,665 shares of the company’s stock worth $4,047,000 after acquiring an additional 12,447 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.